Safety Study of XL844 in Subjects With Chronic Lymphocytic Leukemia
Phase 1
Terminated
- Conditions
- Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
- Registration Number
- NCT00234481
- Lead Sponsor
- Exelixis
- Brief Summary
The purpose of this study is to assess the safety and tolerability of different doses of XL844 when given orally to adults with recurrent or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- Patients with recurrent or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
- Prior treatment with at least 2 systemic chemotherapy regimens for CLL
- Life expectancy of >3 months
- Adequate liver and kidney function
- Absolute neutrophil count ≥500/mm3; platelets ≥50,000/dL; hemoglobin ≥9 g/dL
- Willing to use accepted method of contraception during the course of the study
- Negative pregnancy test (females)
- Written informed consent
Exclusion Criteria
- Chemotherapy or radiotherapy within 4-6 weeks of the start of treatment (depending on the therapy)
- Investigational drug within 30 days of the start of treatment
- Uncontrolled intercurrent illness such as infection or cardiovascular disease
- Pregnant or breastfeeding women
- Subjects known to be HIV positive
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (3)
UCSD Moores Cancer Center
🇺🇸San Diego, California, United States
City of Hope National Cancer Center
🇺🇸Duarte, California, United States
UT MD Anderson Cancer Center
🇺🇸Houston, Texas, United States